Loading…
Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status
A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yello...
Saved in:
| Published in: | The Journal of infectious diseases 1983-12, Vol.148 (6), p.1055-1060 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c416t-2e68620894e0bf1d68482faa1ea0bf1e69ad61d0d78320ccf17bfd2bd4bb23543 |
|---|---|
| cites | |
| container_end_page | 1060 |
| container_issue | 6 |
| container_start_page | 1055 |
| container_title | The Journal of infectious diseases |
| container_volume | 148 |
| creator | Scott, R. McN Eckels, K. H. Bancroft, W. H. Summers, P. L. McCown, J. M. Anderson, J. H. Russell, P. K. |
| description | A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yellow fever-immune volunteers, with a 50% immunizing dose of 103.3 plaque-forming units. In the group not immune to yellow fever, some but not all recipients of each vaccine dilution were immunized, and no 50% immunizing dose could be estimated. Volunteers immune to yellow fever developed adequate titers of neutralizing antibody to dengue 2 virus and maintained them for at least three years; those not immune to yellow fever developed lower antibody titers that disappeared within six months in half of the cases. More than 40 isolates of dengue 2 virus from 12 volunteers retained the in vitro growth characteristics of the vaccine virus; this result affirmed the genetic stability of the virus. Common clinical signs in immunized individuals were leukopenia (55%), macular rash (15%), and fever (10%). |
| doi_str_mv | 10.1093/infdis/148.6.1055 |
| format | article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_80814202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30133833</jstor_id><sourcerecordid>30133833</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-2e68620894e0bf1d68482faa1ea0bf1e69ad61d0d78320ccf17bfd2bd4bb23543</originalsourceid><addsrcrecordid>eNqFkEtv1DAURi0EKkPhB7BA8gKxS-tHcu2wQx36kCqBCpTHxnKcG5SS2IPt8Pj3eDTDsGRlX5_vfrIOIU85O-GslaejH_oxnfJan0B5aZp7ZMUbqSoALu-TFWNCVFy37UPyKKU7xlgtQR2RI4CmEVqvyMc1-q8LUkFvrXOjx5d0HRLSG0yb4Mtl9PQ2TIvPiDFtpxucbB6DpznQzzhN4Sc9xx8Y6dU8Lx7pu2zzkh6TB4OdEj7Zn8fkw_nr92eX1fWbi6uzV9eVqznkSiBoEEy3NbJu4D3oWovBWo52OyO0tgfes15pKZhzA1fd0Iuur7tOyKaWx-TFrncTw_cFUzbzmFz5lvUYlmQ007wWTPw3yKUCpZkqQb4LuhhSijiYTRxnG38bzszWutlZN8W6AbO1Xnae7cuXbsb-sLHXXPjzPbfJ2WmI1rvS8DfWSg1MqH81dymHeMCScSm1lIVXOz6mjL8O3MZvBpRUjbn89MVo0cq3awBzIf8AF16jpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>13767807</pqid></control><display><type>article</type><title>Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford University Press Archive</source><creator>Scott, R. McN ; Eckels, K. H. ; Bancroft, W. H. ; Summers, P. L. ; McCown, J. M. ; Anderson, J. H. ; Russell, P. K.</creator><creatorcontrib>Scott, R. McN ; Eckels, K. H. ; Bancroft, W. H. ; Summers, P. L. ; McCown, J. M. ; Anderson, J. H. ; Russell, P. K.</creatorcontrib><description>A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yellow fever-immune volunteers, with a 50% immunizing dose of 103.3 plaque-forming units. In the group not immune to yellow fever, some but not all recipients of each vaccine dilution were immunized, and no 50% immunizing dose could be estimated. Volunteers immune to yellow fever developed adequate titers of neutralizing antibody to dengue 2 virus and maintained them for at least three years; those not immune to yellow fever developed lower antibody titers that disappeared within six months in half of the cases. More than 40 isolates of dengue 2 virus from 12 volunteers retained the in vitro growth characteristics of the vaccine virus; this result affirmed the genetic stability of the virus. Common clinical signs in immunized individuals were leukopenia (55%), macular rash (15%), and fever (10%).</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/148.6.1055</identifier><identifier>PMID: 6655288</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adolescent ; Adult ; Antibodies ; Antibodies, Viral - analysis ; Arboviroses ; Biological and medical sciences ; Complement Fixation Tests ; Dengue ; Dengue - prevention & control ; Dengue fevers ; dengue virus ; Dengue Virus - immunology ; Dengue Virus - physiology ; Dosage ; Dose-Response Relationship, Immunologic ; Female ; Hemagglutination Inhibition Tests ; Human viral diseases ; Humans ; Infectious diseases ; Male ; Medical research ; Medical sciences ; Middle Aged ; Miscellaneous ; Neutralization Tests ; Neutralizing antibodies ; Tropical medicine ; Tropical viral diseases ; Vaccination ; Vaccines ; Vaccines, Attenuated - immunology ; Viral cardiopathies ; Viral diseases ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology ; Viremia ; Viruses ; Volunteerism ; Yellow fever ; yellow fever virus ; Yellow fever virus - immunology</subject><ispartof>The Journal of infectious diseases, 1983-12, Vol.148 (6), p.1055-1060</ispartof><rights>Copyright 1983 The University of Chicago</rights><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-2e68620894e0bf1d68482faa1ea0bf1e69ad61d0d78320ccf17bfd2bd4bb23543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30133833$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30133833$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,58213,58446</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9386027$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6655288$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, R. McN</creatorcontrib><creatorcontrib>Eckels, K. H.</creatorcontrib><creatorcontrib>Bancroft, W. H.</creatorcontrib><creatorcontrib>Summers, P. L.</creatorcontrib><creatorcontrib>McCown, J. M.</creatorcontrib><creatorcontrib>Anderson, J. H.</creatorcontrib><creatorcontrib>Russell, P. K.</creatorcontrib><title>Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yellow fever-immune volunteers, with a 50% immunizing dose of 103.3 plaque-forming units. In the group not immune to yellow fever, some but not all recipients of each vaccine dilution were immunized, and no 50% immunizing dose could be estimated. Volunteers immune to yellow fever developed adequate titers of neutralizing antibody to dengue 2 virus and maintained them for at least three years; those not immune to yellow fever developed lower antibody titers that disappeared within six months in half of the cases. More than 40 isolates of dengue 2 virus from 12 volunteers retained the in vitro growth characteristics of the vaccine virus; this result affirmed the genetic stability of the virus. Common clinical signs in immunized individuals were leukopenia (55%), macular rash (15%), and fever (10%).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies</subject><subject>Antibodies, Viral - analysis</subject><subject>Arboviroses</subject><subject>Biological and medical sciences</subject><subject>Complement Fixation Tests</subject><subject>Dengue</subject><subject>Dengue - prevention & control</subject><subject>Dengue fevers</subject><subject>dengue virus</subject><subject>Dengue Virus - immunology</subject><subject>Dengue Virus - physiology</subject><subject>Dosage</subject><subject>Dose-Response Relationship, Immunologic</subject><subject>Female</subject><subject>Hemagglutination Inhibition Tests</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Neutralization Tests</subject><subject>Neutralizing antibodies</subject><subject>Tropical medicine</subject><subject>Tropical viral diseases</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Viral cardiopathies</subject><subject>Viral diseases</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><subject>Viremia</subject><subject>Viruses</subject><subject>Volunteerism</subject><subject>Yellow fever</subject><subject>yellow fever virus</subject><subject>Yellow fever virus - immunology</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><recordid>eNqFkEtv1DAURi0EKkPhB7BA8gKxS-tHcu2wQx36kCqBCpTHxnKcG5SS2IPt8Pj3eDTDsGRlX5_vfrIOIU85O-GslaejH_oxnfJan0B5aZp7ZMUbqSoALu-TFWNCVFy37UPyKKU7xlgtQR2RI4CmEVqvyMc1-q8LUkFvrXOjx5d0HRLSG0yb4Mtl9PQ2TIvPiDFtpxucbB6DpznQzzhN4Sc9xx8Y6dU8Lx7pu2zzkh6TB4OdEj7Zn8fkw_nr92eX1fWbi6uzV9eVqznkSiBoEEy3NbJu4D3oWovBWo52OyO0tgfes15pKZhzA1fd0Iuur7tOyKaWx-TFrncTw_cFUzbzmFz5lvUYlmQ007wWTPw3yKUCpZkqQb4LuhhSijiYTRxnG38bzszWutlZN8W6AbO1Xnae7cuXbsb-sLHXXPjzPbfJ2WmI1rvS8DfWSg1MqH81dymHeMCScSm1lIVXOz6mjL8O3MZvBpRUjbn89MVo0cq3awBzIf8AF16jpA</recordid><startdate>198312</startdate><enddate>198312</enddate><creator>Scott, R. McN</creator><creator>Eckels, K. H.</creator><creator>Bancroft, W. H.</creator><creator>Summers, P. L.</creator><creator>McCown, J. M.</creator><creator>Anderson, J. H.</creator><creator>Russell, P. K.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>198312</creationdate><title>Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status</title><author>Scott, R. McN ; Eckels, K. H. ; Bancroft, W. H. ; Summers, P. L. ; McCown, J. M. ; Anderson, J. H. ; Russell, P. K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-2e68620894e0bf1d68482faa1ea0bf1e69ad61d0d78320ccf17bfd2bd4bb23543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies</topic><topic>Antibodies, Viral - analysis</topic><topic>Arboviroses</topic><topic>Biological and medical sciences</topic><topic>Complement Fixation Tests</topic><topic>Dengue</topic><topic>Dengue - prevention & control</topic><topic>Dengue fevers</topic><topic>dengue virus</topic><topic>Dengue Virus - immunology</topic><topic>Dengue Virus - physiology</topic><topic>Dosage</topic><topic>Dose-Response Relationship, Immunologic</topic><topic>Female</topic><topic>Hemagglutination Inhibition Tests</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Neutralization Tests</topic><topic>Neutralizing antibodies</topic><topic>Tropical medicine</topic><topic>Tropical viral diseases</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Viral cardiopathies</topic><topic>Viral diseases</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><topic>Viremia</topic><topic>Viruses</topic><topic>Volunteerism</topic><topic>Yellow fever</topic><topic>yellow fever virus</topic><topic>Yellow fever virus - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, R. McN</creatorcontrib><creatorcontrib>Eckels, K. H.</creatorcontrib><creatorcontrib>Bancroft, W. H.</creatorcontrib><creatorcontrib>Summers, P. L.</creatorcontrib><creatorcontrib>McCown, J. M.</creatorcontrib><creatorcontrib>Anderson, J. H.</creatorcontrib><creatorcontrib>Russell, P. K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, R. McN</au><au>Eckels, K. H.</au><au>Bancroft, W. H.</au><au>Summers, P. L.</au><au>McCown, J. M.</au><au>Anderson, J. H.</au><au>Russell, P. K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1983-12</date><risdate>1983</risdate><volume>148</volume><issue>6</issue><spage>1055</spage><epage>1060</epage><pages>1055-1060</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>A live dengue 2 vaccine was tested in 38 volunteers in an evaluation of the safety, infectivity, and immunogenicity of doses of 101.8–105.5 plaque-forming units. Twenty yellow fever-immune and 18 yellow fever-nonimmune individuals received 0.5 ml of vaccine sc. Immunization was dose related in yellow fever-immune volunteers, with a 50% immunizing dose of 103.3 plaque-forming units. In the group not immune to yellow fever, some but not all recipients of each vaccine dilution were immunized, and no 50% immunizing dose could be estimated. Volunteers immune to yellow fever developed adequate titers of neutralizing antibody to dengue 2 virus and maintained them for at least three years; those not immune to yellow fever developed lower antibody titers that disappeared within six months in half of the cases. More than 40 isolates of dengue 2 virus from 12 volunteers retained the in vitro growth characteristics of the vaccine virus; this result affirmed the genetic stability of the virus. Common clinical signs in immunized individuals were leukopenia (55%), macular rash (15%), and fever (10%).</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>6655288</pmid><doi>10.1093/infdis/148.6.1055</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1983-12, Vol.148 (6), p.1055-1060 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80814202 |
| source | JSTOR Archival Journals and Primary Sources Collection; Oxford University Press Archive |
| subjects | Adolescent Adult Antibodies Antibodies, Viral - analysis Arboviroses Biological and medical sciences Complement Fixation Tests Dengue Dengue - prevention & control Dengue fevers dengue virus Dengue Virus - immunology Dengue Virus - physiology Dosage Dose-Response Relationship, Immunologic Female Hemagglutination Inhibition Tests Human viral diseases Humans Infectious diseases Male Medical research Medical sciences Middle Aged Miscellaneous Neutralization Tests Neutralizing antibodies Tropical medicine Tropical viral diseases Vaccination Vaccines Vaccines, Attenuated - immunology Viral cardiopathies Viral diseases Viral Vaccines - adverse effects Viral Vaccines - immunology Viremia Viruses Volunteerism Yellow fever yellow fever virus Yellow fever virus - immunology |
| title | Dengue 2 Vaccine: Dose Response in Volunteers in Relation to Yellow Fever Immune Status |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A12%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dengue%202%20Vaccine:%20Dose%20Response%20in%20Volunteers%20in%20Relation%20to%20Yellow%20Fever%20Immune%20Status&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Scott,%20R.%20McN&rft.date=1983-12&rft.volume=148&rft.issue=6&rft.spage=1055&rft.epage=1060&rft.pages=1055-1060&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/148.6.1055&rft_dat=%3Cjstor_proqu%3E30133833%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-2e68620894e0bf1d68482faa1ea0bf1e69ad61d0d78320ccf17bfd2bd4bb23543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=13767807&rft_id=info:pmid/6655288&rft_jstor_id=30133833&rfr_iscdi=true |